Genomma Lab Internacional, S.A.B. de C.V. (LABB.MX)
- Previous Close
15.80 - Open
15.80 - Bid 16.30 x 50000
- Ask 16.36 x 194200
- Day's Range
15.80 - 16.48 - 52 Week Range
12.39 - 16.48 - Volume
3,701,871 - Avg. Volume
3,583,900 - Market Cap (intraday)
15.722B - Beta (5Y Monthly) --
- PE Ratio (TTM)
10.79 - EPS (TTM)
1.51 - Earnings Date Jul 24, 2024 - Jul 29, 2024
- Forward Dividend & Yield 0.78 (4.80%)
- Ex-Dividend Date Mar 22, 2024
- 1y Target Est
16.41
Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Latin America. It develops, sells, and markets a range of branded products in the categories of anti-acne products, self-diagnosis, antibacterial, cream to improve the texture of scarred skin, shampoos, dandruff shampoos, soaps, razors, products to prevent hair loss, ointment for muscle pain, anti-fungal treatments for the relief of colitis, products to counter stress levels, anti-wrinkles, antacids, anti-ulcers, anti-flu, protection and sexual improvement, treatments against hemorrhoids, against varicose veins, osteoarthritis, ophthalmic medications, and infant nutrition. The company was incorporated in 1996 and is based in Mexico City, Mexico.
www.genommalab.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: LABB.MX
Performance Overview: LABB.MX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LABB.MX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LABB.MX
Valuation Measures
Market Cap
15.76B
Enterprise Value
20.85B
Trailing P/E
10.82
Forward P/E
9.26
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.92
Price/Book (mrq)
1.61
Enterprise Value/Revenue
1.22
Enterprise Value/EBITDA
6.51
Financial Highlights
Profitability and Income Statement
Profit Margin
6.34%
Return on Assets (ttm)
9.49%
Return on Equity (ttm)
10.37%
Revenue (ttm)
16.49B
Net Income Avi to Common (ttm)
1.04B
Diluted EPS (ttm)
1.51
Balance Sheet and Cash Flow
Total Cash (mrq)
1.14B
Total Debt/Equity (mrq)
63.71%
Levered Free Cash Flow (ttm)
2.1B
Research Analysis: LABB.MX
Company Insights: LABB.MX
LABB.MX does not have Company Insights